drugset / Trial / NCT01392638

Effects of Sildenafil in Resistant Hypertensives and Genetic Polymorphism

NCT01392638

Non-randomizedCrossoverSingle-blindTreatment

Summary

Sildenafil citrate slightly reduces blood pressure in treated hypertensives patients. However, it is unknown if the simultaneous use of sildenafil plus, at least, 3 classes of antihypertensive agents in patients with resistant arterial hypertension may have a synergic effect on the patients blood pressure. Moreover, sildenafil improves the endogen nitric oxide effects. The nitric oxide is an important signaling molecule in the body that contributes to vessel homeostasis by inhibiting vascular smooth muscle contraction and growth. Hypertension often impaired NO pathways. Nitric oxide is produced by an enzyme, called nitric oxide synthase (NOS3), that show some genetics variants, which means that this enzyme can be different from person to person. Therefore, the objective of the present study is to examine the influence of a genetic variant (known to affect NOS3 levels) in sildenafil acute effects on hemodynamic and cardiovascular function. The investigators hypothesis is that individuals with the genetic variant associated to higher levels of NOS3 will have more benefits from sildenafil treatment.

Timeline

Start
2010-07
Primary completion
2012-07
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sildenafil Unknown 37.5 mg
Comparator Sildenafil Unknown 50 mg
Comparator Sildenafil Unknown 100 mg

Indications